Literature DB >> 23080343

Clinicopathological features of ulcerative colitis-associated colorectal cancer pointing to efficiency of surveillance colonoscopy in a large retrospective Japanese cohort.

Hiroki Matsuoka1, Hiroki Ikeuchi, Motoi Uchino, Toshihiro Bando, Yoshio Takesue, Takayuki Nishigami, Naohiro Tomita.   

Abstract

PURPOSE: Cancer surveillance has been conducted in patients with ulcerative colitis (UC), and the number of operative cases of ulcerative colitis-associated colorectal cancer (UC-CRC) has been increasing. The aim of this study was to clarify the clinicopathological features and prognoses of UC-CRC patients and the relationship between surveillance colonoscopy and UC-CRC.
METHODS: The clinical records of 1,274 UC patients who required surgery between 1984 and 2010 at a single institution were reviewed retrospectively. Of these, 83 patients had CRC (107 sections). All cases were extracted from the database, along with their clinicopathological data.
RESULTS: The 5-year survival rate of the UC-CRC group was 89 %. The 5-year survival rate was 100 % in stages 0 and II, 96 % in stage I, 56 % in stage III, and 0 % in stage IV. Surveillance colonoscopy was performed for 40 of the 83 patients. Of 40 patients, 30 with UC who underwent surveillance colonoscopies and 22 of 43 patients without surveillance colonoscopies were in stages 0 to I (P = 0.04).
CONCLUSION: The number of UC-CRC patients who are diagnosed by surveillance colonoscopy is increasing, and many of them are detected in the very early stages (stages 0 or I). Thus, the survival rate of UC-CRC is better than before. Surveillance colonoscopy proofs efficient as CRC are detected in earlier stages.

Entities:  

Mesh:

Year:  2012        PMID: 23080343     DOI: 10.1007/s00384-012-1592-6

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  22 in total

Review 1.  Inflammatory bowel disease: clinical aspects and established and evolving therapies.

Authors:  Daniel C Baumgart; William J Sandborn
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

2.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

3.  Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study.

Authors:  Ane B Jensen; Mette Larsen; Mette Gislum; Mette V Skriver; Peter Jepsen; Bente Nørgaard; Henrik T Sørensen
Journal:  Am J Gastroenterol       Date:  2006-06       Impact factor: 10.864

4.  Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.

Authors:  D Pinczowski; A Ekbom; J Baron; J Yuen; H O Adami
Journal:  Gastroenterology       Date:  1994-07       Impact factor: 22.682

5.  American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer.

Authors:  T Byers; B Levin; D Rothenberger; G D Dodd; R A Smith
Journal:  CA Cancer J Clin       Date:  1997 May-Jun       Impact factor: 508.702

Review 6.  Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.

Authors:  Erick P Chan; Gary R Lichtenstein
Journal:  Gastroenterol Clin North Am       Date:  2006-09       Impact factor: 3.806

7.  5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.

Authors:  Charles N Bernstein; Zoann Nugent; James F Blanchard
Journal:  Am J Gastroenterol       Date:  2011-03-15       Impact factor: 10.864

8.  Survival with carcinoma arising in mucosal ulcerative colitis.

Authors:  I C Lavery; R A Chiulli; D G Jagelman; V W Fazio; F L Weakley
Journal:  Ann Surg       Date:  1982-04       Impact factor: 12.969

9.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

Review 10.  Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.

Authors:  David T Rubin; Marcia R Cruz-Correa; Christoph Gasche; Jeremy R Jass; Gary R Lichtenstein; Elizabeth A Montgomery; Robert H Riddell; Matthew D Rutter; Thomas A Ullman; Fernando S Velayos; Steven Itzkowitz
Journal:  Inflamm Bowel Dis       Date:  2008-02       Impact factor: 5.325

View more
  10 in total

Review 1.  Strategies for detecting colon cancer in patients with inflammatory bowel disease.

Authors:  William A Bye; Tran M Nguyen; Claire E Parker; Vipul Jairath; James E East
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

2.  Surgical resections of ulcerative colitis associated with dysplasia or carcinoma.

Authors:  Shinichi Sameshima; Shinichiro Koketsu; Emiko Takeshita; Yawara Kubota; Takashi Okuyama; Kazuyuki Saito; Yoshihiko Ueda; Toshio Sawada; Masatoshi Oya
Journal:  World J Surg Oncol       Date:  2015-02-21       Impact factor: 2.754

3.  Qingchang Wenzhong Decoction Ameliorates Dextran Sulphate Sodium-Induced Ulcerative Colitis in Rats by Downregulating the IP10/CXCR3 Axis-Mediated Inflammatory Response.

Authors:  Tang-You Mao; Rui Shi; Wei-Han Zhao; Yi Guo; Kang-Li Gao; Chen Chen; Tian-Hong Xie; Jun-Xiang Li
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-16       Impact factor: 2.629

4.  Effects of indigo naturalis on colonic mucosal injuries and inflammation in rats with dextran sodium sulphate-induced ulcerative colitis.

Authors:  Yunliang Wang; Lijuan Liu; Yi Guo; Tangyou Mao; Rui Shi; Junxiang Li
Journal:  Exp Ther Med       Date:  2017-06-28       Impact factor: 2.447

5.  Qingchang Wenzhong Decoction Attenuates DSS-Induced Colitis in Rats by Reducing Inflammation and Improving Intestinal Barrier Function via Upregulating the MSP/RON Signalling Pathway.

Authors:  Tangyou Mao; Junxiang Li; Lijuan Liu; Weihan Zhao; Yuyue Liu; Kangli Gao; Yi Guo; Tianhong Xie; Ningfei Li; Rui Shi
Journal:  Evid Based Complement Alternat Med       Date:  2017-10-12       Impact factor: 2.629

6.  Prognosis of ulcerative colitis colorectal cancer vs. sporadic colorectal cancer: propensity score matching analysis.

Authors:  Yoon Dae Han; Mahdi Hussain Al Bandar; Audrius Dulskas; Min Soo Cho; Hyuk Hur; Byung Soh Min; Kang Young Lee; Nam Kyu Kim
Journal:  BMC Surg       Date:  2017-03-21       Impact factor: 2.102

7.  Risk of Colorectal Cancer in Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis.

Authors:  Qing Zhou; Zhao-Feng Shen; Ben-Sheng Wu; Cheng-Biao Xu; Zhong-Qi He; Tuo Chen; Hong-Tao Shang; Chao-Fan Xie; Si-Yi Huang; Yu-Gen Chen; Hai-Bo Chen; Shu-Tang Han
Journal:  Gastroenterol Res Pract       Date:  2019-11-03       Impact factor: 2.260

8.  Bone marrow mesenchymal stem cells combined with Atractylodes macrocephala polysaccharide attenuate ulcerative colitis.

Authors:  Zhijuan Zheng; Junqing Wang
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

9.  Clinicopathological characteristics of cancer associated with Crohn's disease.

Authors:  Hirofumi Sasaki; Hiroki Ikeuchi; Toshihiro Bando; Kei Hirose; Akihiro Hirata; Teruhiro Chohno; Yuki Horio; Naohiro Tomita; Seiichi Hirota; Yoshihiro Ide; Yasuaki Tsuchida; Motoi Uchino
Journal:  Surg Today       Date:  2016-04-19       Impact factor: 2.549

Review 10.  Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.

Authors:  Taku Kobayashi; Tadakazu Hisamatsu; Yasuo Suzuki; Haruhiko Ogata; Akira Andoh; Toshimitsu Araki; Ryota Hokari; Hideki Iijima; Hiroki Ikeuchi; Yoh Ishiguro; Shingo Kato; Reiko Kunisaki; Takayuki Matsumoto; Satoshi Motoya; Masakazu Nagahori; Shiro Nakamura; Hiroshi Nakase; Tomoyuki Tsujikawa; Makoto Sasaki; Kaoru Yokoyama; Naoki Yoshimura; Kenji Watanabe; Miiko Katafuchi; Mamoru Watanabe; Toshifumi Hibi
Journal:  Intest Res       Date:  2018-04-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.